21 CFR 211.101: Charge-in of components

Requires manufacturers to formulate batches for at least 100% of labeled active ingredient, identify subdivided components, and have a second person verify QC release, correct weights, labeling, and addition of each component, unless automated.

Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals · Subpart F, Production and Process Controls

How FDA words it

The opening lines investigators use most when they cite 211.101, from the 483s we hold.

Each component is not added to the batch by one person and verified by a second person..Most used
Each component is not added to a batch by one person and verified by a second person.211.101(d)
Each container of component dispensed to manufacturing is not examined by a second person to assure that the weight or measure is correct as stated in the batch records.211.101(d)

Cited over time

483s citing 211.101, by year

Most citations in 2020. Bars are relative to the busiest year. *2026 to date.

Years shown: 2017 to 2026. The busiest year was 2020.

Recent 483s citing 211.101

See all 483s citing 211.101

The regulation text

§ 211.101 Charge-in of components.

Written production and control procedures shall include the following, which are designed to assure that the drug products produced have the identity, strength, quality, and purity they purport or are represented to possess:

(a)The batch shall be formulated with the intent to provide not less than 100 percent of the labeled or established amount of active ingredient.

(b)Components for drug product manufacturing shall be weighed, measured, or subdivided as appropriate. If a component is removed from the original container to another, the new container shall be identified with the following information:

(1)Component name or item code;

(2)Receiving or control number;

(3)Weight or measure in new container;

(4)Batch for which component was dispensed, including its product name, strength, and lot number.

(c)Weighing, measuring, or subdividing operations for components shall be adequately supervised. Each container of component dispensed to manufacturing shall be examined by a second person to assure that:

(1)The component was released by the quality control unit;

(2)The weight or measure is correct as stated in the batch production records;

(3)The containers are properly identified. If the weighing, measuring, or subdividing operations are performed by automated equipment under § 211.68, only one person is needed to assure paragraphs (c)(1), (c)(2), and (c)(3) of this section.

(d)Each component shall either be added to the batch by one person and verified by a second person or, if the components are added by automated equipment under § 211.68, only verified by one person.

[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]

Questions

What does 21 CFR 211.101 require?

Requires manufacturers to formulate batches for at least 100% of labeled active ingredient, identify subdivided components, and have a second person verify QC release, correct weights, labeling, and addition of each component, unless automated.

How do FDA investigators word a 211.101 observation?

The most common opening is: “Each component is not added to the batch by one person and verified by a second person..”

Which sections are cited alongside 211.101?

In the same 483s, investigators most often also cite 211.67 (Equipment cleaning and maintenance), 211.192 (Production record review), 211.22 (Responsibilities of quality control unit), 211.160 (General requirements).